When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Hims & Hers (HIMS) rallied this morning after earnings, reversing initial selling action following the report. Diane King Hall believes a huge jump in revenue and its Wegovy deal are behind the positive sentiment.

NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan.

BARTLETT, Tenn. , May 6, 2025 /PRNewswire/ -- SurgePays, Inc. (NASDAQ: SURG) ("SurgePays" or the "Company"), a wireless and point-of-sale technology company, will release its first quarter 2025 financial results, after the close of trading on Tuesday, May 13, 2025.

Affinity Bancshares saw a net profit of $5.44M in 2024, despite a 15% decrease in EPS due to increased non-interest expenses. The bank's net interest income rose to $29.2M, driven by higher interest income and controlled interest expenses. With a solid loan book and minimal loan loss provisions, Affinity's tangible book value per share increased to $17.30.

NEW YORK, NY / ACCESS Newswire / May 6, 2025 / If you suffered a loss on your TFI International Inc. (NYSE:TFII) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/tfi-international-inc-lawsuit-submission-form?prid=147146&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK--(BUSINESS WIRE)--Oliver Wyman, a global leader in management consulting and a business of Marsh McLennan (NYSE:MMC) today launches its latest Labor Cost per Vehicle analysis. As the automotive industry faces economic headwinds, shifting global production landscapes, and rising geopolitical tensions, this comparative analysis examines the labor cost per vehicle (LCPV), a critical metric that influences automaker profitability and competitiveness. Getting Under the Hood of Automotive La.

CrowdStrike (CRWD -0.95%) is still recovering from the reputational damage caused by an outage for millions of customers.

PHILADELPHIA, PA / ACCESS Newswire / May 6, 2025 / The law firm of Kaskela Law LLC announces that it is investigating MaxLinear, Inc. (NASDAQ:MXL) on behalf of the company's shareholders. Click here to receive additional information: https://kaskelalaw.com/case/maxlinear/ Since January 2025, shares of MaxLinear's common stock have declined in value from a trading price of over $22.00 per share to a current trading price of less than $11.00 per share, a decline of over 50% in value.

NEW YORK, NY / ACCESS Newswire / May 6, 2025 / If you suffered a loss on your Treace Medical Concepts, Inc. (NASDAQ:TMCI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/treace-medical-concepts-inc-lawsuit-submission-form-2?prid=147145&wire=1 or contact Joseph E. Levi, Esq.

Leidos Holdings, Inc. (NYSE:LDOS ) Q1 2025 Earnings Call May 6, 2025 8:00 AM ET Company Participants Stuart Davis - IR Tom Bell - CEO Chris Cage - CFO Conference Call Participants Peter Arment - Robert W. Baird Joshua Korn - Barclays Bank Sheila Kahyaoglu - Jefferies Colin Canfield - Cantor Fitzgerald Mariana Mora - Bank of America Securities Jason Gursky - Citigroup Inc. Tyler Barishaw - Scott Mikus - Melius Research Kenneth Herbert - RBC Capital Markets Noah Poponak - Goldman Sachs Gavin Parsons - UBS Investment Bank Gautam Khanna - TD Cowen Operator Greetings.

AECOM (NYSE:ACM ) Q2 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Will Gabrielski - Senior Vice President, Finance, Treasury & Investor Relations Troy Rudd - Chief Executive Officer Lara Poloni - President Gaurav Kapoor - Chief Financial Officer & Chief Operations Officer Conference Call Participants Michael Feniger - Bank of America Sabahat Khan - RBC Capital Markets Andy Kaplowitz - Citigroup Adam Bubes - Goldman Sachs Steven Fisher - UBS Jamie Cook - Truist Securities Adam Thalhimer - Thompson Davis Operator Good morning, and welcome to the AECOM Second Quarter 2025 Conference Call. I would …

The gold market rallied again on Tuesday, as we are looking to break higher levels yet again. At this point, the Fed meeting is going to be front and center, as we look to the Fed to guide us on monetary policy in the future.

Shares of Palantir Technologies (PLTR -13.25%) are falling on Tuesday. The company's stock slid 14.1% as of 10:10 a.m.

Uber is expanding its presence in Turkey with its latest acquisition.

I am upgrading the iShares MSCI India Small-Cap ETF (SMIN) to a buy due to improved valuation, despite technical caution. SMIN has underperformed, down 11% since November 2024, but offers a cheap P/E ratio of 16x and a PEG ratio under 1. The ETF's sector diversification includes 22% Industrials and 16% Financials, with a promising long-term EPS growth rate of 23%.

Get a deeper insight into the potential performance of Primerica (PRI) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.